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ABSTRACT
Anti-N-Methyl D-aspartate receptor (NMDAR) encephalitis is a neuro-inflammatory disorder caused by antibodies
targeting neurons in the central nervous system. Certain viruses break immune tolerance of neuronal proteins and
increase the permeability of blood brain barrier (BBB) to antibodies resulting in post infectious autoimmunity. We report
a case about a 13 years old girl diagnosed as a case of anti-NMDAR encephalitis, who presented with psychiatric
symptoms followed by abnormal movements and encephalopathy, with later development of autonomic instability with
tachycardia and blood pressure at 98th centile. Her thyroid profile initially showed hyperthyroidism with negative
anti-thyroid antibodies with subsequent normalization without anti-thyroid drug. Her SARS-CoV-2 antibody was positive
despite being asymptomatic that had induced autoimmunity in central nervous system and caused transient thyroiditis.
She poorly responded to first tier immune therapy (methylprednisolone pulse & plasmapheresis) but there was
remarkable response to second tier immune therapy with Rituximab, with prompt attainment of ambulation and self
care.
KEY WORDS: Anti-NMDAR encephalitis, Abnormal movements, Encephalopathy, SARS-CoV-2 Ig.
INTRODUCTION:
Anti-N-Methyl
D-aspartate
receptor
(NMDAR)
encephalitis is not rare. First described in 2007, it is
the most frequent autoimmine encephalitis (AE) after
Acute Disseminated Encephalomyelitis (ADEM).1 It
frequently affects young adults, with a strong female
preponderance (4:1).2 Non-paraneoplastic AE is
triggered by infection or environmental factors resulting
in autoantibodies production against cell surface
neuronal antigens. Certain viruses break the immune
tolerance of neuronal proteins and increase
permeability of blood brain barrier to antibodies. There
has been several neurological presentations reported
with severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection, both infectious and
post-infectious. Asymptomatic and mildly symptomatic
children with SARS-CoV-2 infection may not be
identified during the acute illness but later may present
with para-infectious autoimmune phenomenon.2 We
present
a
case
with anti-NMDAR encephalitis as a para-infectious
complication
of
SARS-CoV-2
confirmed
by
SARS-CoV-2antibody.

cycle. Later she developed irrelevant talk and memory
loss. In the 2nd week of illness, she had three episodes
of generalized tonic clonic seizures with worsened
conscious level. There was no preceding history of any
fever, flu like or gastrointestinal symptoms. She was
not vaccinated for COVID. Examination showed an
encephalopathic girl with sustained muscle contraction
causing abnormal dystonic posture, oro-facial
dyskinesia and dystonia of ocular muscles with
generalized upper motor neuron signs. Fundus
examination was normal. She was tachycardiac and
blood pressure was at 98th centile. There was no rash,
joint swelling, alopecia or significant systemic finding.
Family history revealed mother being hypothyroid.
She was thoroughly investigated with cerebrospinal
fluid (CSF) examination showing less than 3 cells,
normal protein and glucose. Her ceruloplasmin and
urinary copper levels were normal and Kaiser-Fleischer
(KF) rings were absent on slit lamp examination.
Considering family history, high blood pressure and
tachycardia, thyroid profile was reviewed and it was
consistent with hyperthyroidism, which later became
normal without any anti-thyroid drug. Thyroid antibodies
(anti-thyroid peroxidase antibody and thyrotropin
receptor antibody) were negative excluding the
possibility of Hashimoto’s encephalopathy. Repeat CSF
for anti NMDAR antibody came out to be positive.

CASE REPORT:
13 years old girl, 2nd in order of 5 siblings, product of
non-consanguineous
marriage,
presented
with
behavioral issues for 1 week in terms of intermittent
aggression and irritability with disturbed sleep wake
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Extensive imaging including MRI brain was normal and
MRI of abdomen and pelvis also excluded the possibility
of any neoplasm. EEG showed slow background with
delta brush pattern (Figure 1). Since there was
multi-system involvement including encephalitis,
thyroiditis and transaminitis, possible viral trigger was

thought of. Viral serologies were sent and only
SARS-CoV-2 antibody came positive, though there was
no history of SARS-CoV-2 infection in past neither any
contact. This ascertained the para-infectious etiology
for the triggered immune response. The investigations
are shown in Table 1.

Figure 1: EEG with delta brush pattern
Table 1: Important investigations

PAKISTAN JOURNAL OF NEUROLOGICAL SCIENCES

17

VOL. 17 (1) JAN-MAR 2022

Immune-therapy
was
given
with
intravenous
methylprednisolone (IVMP) pulses (30mg/kg/day) over 5
days with strict control of blood pressure and seizures
alongside neuroprotective measures. After 2 days of IVMP
completion, there was no clinical response, so therapy was
quickly escalated to plasmapheresis; 5 cycles in 10 days,
but she showed no significant benefit with 1st line therapy.
She had persistent dystonia, dyskinesia and
encephalopathy; though autonomic instability was well
controlled with medications. 2nd line immune-therapy with
rituximab was given; 375mg/m2: 4 doses: 1 week apart.
After the second dose of rituximab, child significantly
showed improvement in her conscious level from Glascow
Coma Scale of 8/15 pre- rituximab to 12/15 post-rituximab
and abnormal movements also settled, though she was still

not ambulatory. After 4th dose, she became ambulatory
with support and was able to self-feed. She was discharged
on oral steroids, anti seizure medication including
levetiracetam at 30mg/kg/day, muscle relaxants and
vitamin supplementation as she was on gavage feeding for
a prolong period, she was given multivitamins in order to
suffice the vitamin need until she was on regular meals. On
follow up at 8 weeks, she was ambulatory unsupported,
with no abnormal movements and good control of seizures.
At 16 weeks follow up, she was ambulatory in all settings,
able to self care, feed and perform daily activities with
ease. However residual deficit in executive function was
still present. The clinical course with respect to treatment
is graphically depicted in figure 2.

Figure 2: Clinical features and response to treatment.
DISCUSSION
Autoimmune encephalitis is an increasingly recognized
neuro-inflammatory disorder in children and adolescents
with anti-NMDAR encephalitis being the most common
type.3 It usually is associated with autoantibodies against
the cell surface or intracellular neuronal antigens.
Possible triggers are viral infection, environmental factors
or teratomas. Previously there have been numerous
studies on post-herpes NMDAR encephalitis.4After novel
coronavirus pandemic that arose from Wuhan, China in
December 2019 and the subsequent discovery of
multisystem inflammatory syndrome in children (MIS-C)
in April 2020, numerous cases of infectious and
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para-infectious immune-mediated disorders have been
reported, triggered by SARS-CoV-2 infection.5 Possible
pathogenesis accounts for dysregulated inflammatory
reaction and production of antibodies that break the
immune tolerance of neuronal proteins and increase
permeability of BBB to these antibodies.6 The most
commonly reported neurological disorders across all age
groups are cerebrovascular accidents, splenial lesions,
Guillain-barre syndrome (GBS), benign intracranial
hypertension, meningo-encephalitis and ADEM.7
Morales S et al studied 10 pediatric patients with
neurological symptoms having confirmed SARS-CoV-2
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infection and found 3 patients with GBS, 2 patients with
optic neuritis, 2 acute ischemic stroke, 1 myositis, and
only 1 patient to be anti-NMDAR positive signifying that
high index of suspicion is needed in cases where
movements complicate encephalopathy.8 Another study
done on 27 patients of pediatric multisystem
inflammatory syndrome, four patients had neurological
manifestations
with
encephalopathy,
headache,
brainstem and cerebellar signs, muscle weakness, and
reduced reflexes but none had NMDAR antibody positive
highlighting the rarity of autoimmune encephalitis
associated with SARS-CoV-2 infection.9

other systems involvements that has not been reported
previously in which she initially had high thyroid
hormones with negative thyroid antibodies which
subsequently became normal, highlighting the possibility
of immune mediated cytokine storm affecting various
other systems. Our patient did not respond to 1st line
immune therapy and was escalated to 2nd line with
rituximab which showed promising results without
significant side effects. There has been studies on
anti-NMDAR encephalitis being refractory to 1st line
treatment but responded well to 2nd line immune
therapy with minimal side effects like in our case.13

Age at which children presented in previous case reports
had been variable from as young as 23 months reported
by Burr et al10 to adolescent male 17 years ( Moideen et
al)11 and female 18 years (Allahyari F et al).12Children
with
autoimmune
encephalitis
presents
with
polysymptoms including behavioral issues, psychiatric
symptoms, disturbed sleep wake cycle, mutism,
seizures, abnormal movements and neurocognitive
deficits like our index case.3 Considering the
polysymptoms,
the
diagnosis
of
autoimmune
encephalitis was considered in this case and
investigation for possible triggers were carried out which
only revealed SARS-CoV-2 antibody.Our patient also had

The neurological presentation of SARS-CoV2 in the
pediatric age group is still surfacing. We need to brace
ourselves up with newer presentations as we are still in
the middle of this pandemic situation which seems to
linger on for some time. We believe this case report will
further broaden the horizon of immune mediated
neurological disorder associated with post-SARS-CoV2
infection.
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